New Zealand markets closed

Johnson & Johnson (JNJ)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
158.19+0.23 (+0.15%)
At close: 04:00PM EDT
158.40 +0.21 (+0.13%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close157.96
Open158.20
Bid158.59 x 800
Ask158.58 x 1000
Day's range158.11 - 159.14
52-week range144.95 - 175.97
Volume6,067,951
Avg. volume7,161,757
Market cap381.203B
Beta (5Y monthly)0.53
PE ratio (TTM)30.42
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yield4.76 (3.01%)
Ex-dividend date16 Feb 2024
1y target estN/A
  • GlobeNewswire

    Artelo Biosciences Selected as a Finalist in Johnson & Johnson’s Innovation Challenge

    ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced its selection as a finalist in Johnson & Johnson’s (“J&J’s”; NYSE: JNJ) Innovation Challenge. Thi

  • Business Wire

    Johnson & Johnson to Host Investor Conference Call on First-Quarter Results

    NEW BRUNSWICK, N.J., March 11, 2024--Johnson & Johnson (NYSE: JNJ) will host a conference call for investors at 8:30 a.m. (Eastern Time) on Tuesday, April 16th to review first-quarter results. Joaquin Duato, Chairman and Chief Executive Officer, Joseph J. Wolk, Executive Vice President and Chief Financial Officer and Jessica Moore, Vice President, Investor Relations will host the call. The question and answer portion of the call will also include additional members of Johnson & Johnson’s executi

  • Business Wire

    Johnson & Johnson Completes Acquisition of Ambrx

    NEW BRUNSWICK, N.J., March 07, 2024--Johnson & Johnson (NYSE: JNJ) announced today it has successfully completed the acquisition of Ambrx Biopharma, Inc., a clinical-stage biopharmaceutical company with a proprietary synthetic biology technology platform to design and develop next-generation antibody drug conjugates (ADCs), in an all-cash merger transaction for a total equity value of approximately $2.0 billion, or $1.9 billion net of estimated cash acquired, as announced on January 8, 2024. The